XNAS · Healthcare · Biotechnology
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.42 | -0.38 | +9.52% | $0 | ✅ Beat | +0.00% | +6.92% | -13.85% |
| 2026-03-03 | Q4 2025 | -0.45 | -0.48 | -6.67% | $0 | ❌ Miss | +0.00% | +5.18% | +35.06% |
| 2025-11-12 |
| Q3 2025 |
| -0.45 |
| -0.32 |
| +28.89% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.46 | -0.49 | -6.52% | $0 | ❌ Miss | +0.98% | -1.63% | -0.13% |
| 2025-03-13 | Q4 2024 | -0.52 | -0.46 | +11.54% | $0 | ✅ Beat | +2.22% | +3.10% | -15.28% |
| 2024-11-13 | Q3 2024 | -0.50 | -0.48 | +4.00% | $0 | ✅ Beat | -3.41% | -1.43% | -10.27% |
| 2024-08-13 | Q2 2024 | -0.55 | -0.41 | +25.45% | $0 | ✅ Beat | +1.30% | +3.62% | +3.76% |
| 2024-05-14 | Q1 2024 | -0.57 | -0.54 | +5.26% | $0 | ✅ Beat | +0.54% | -4.06% | -7.75% |
Showing last 8 quarters.